We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > UMCG

News List

Phase 2 Trials from Akston COVID-19 Vaccine Candidate americanpharmaceuticalreview
August 09, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate.
Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine americanpharmaceuticalreview
August 06, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate.
Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine americanpharmaceuticalreview
April 14, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first participants have been dosed in an open-label trial of AKS-452, its COVID-19 vaccine candidate.